Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Vivos Therapeutics (VVOS) Net Income towards Common Stockholders (2020 - 2025)

Vivos Therapeutics has reported Net Income towards Common Stockholders over the past 6 years, most recently at -$7.0 million for Q4 2025.

  • Quarterly Net Income towards Common Stockholders fell 145.99% to -$7.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$21.2 million through Dec 2025, down 90.65% year-over-year, with the annual reading at -$21.2 million for FY2025, 90.64% down from the prior year.
  • Net Income towards Common Stockholders was -$7.0 million for Q4 2025 at Vivos Therapeutics, down from -$5.4 million in the prior quarter.
  • Over five years, Net Income towards Common Stockholders peaked at -$1.7 million in Q1 2023 and troughed at -$7.4 million in Q4 2021.
  • The 5-year median for Net Income towards Common Stockholders is -$4.6 million (2023), against an average of -$4.5 million.
  • Year-over-year, Net Income towards Common Stockholders tumbled 164.3% in 2021 and then soared 68.05% in 2023.
  • A 5-year view of Net Income towards Common Stockholders shows it stood at -$7.4 million in 2021, then grew by 17.64% to -$6.1 million in 2022, then surged by 30.05% to -$4.3 million in 2023, then surged by 33.62% to -$2.8 million in 2024, then crashed by 145.99% to -$7.0 million in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Net Income towards Common Stockholders are -$7.0 million (Q4 2025), -$5.4 million (Q3 2025), and -$5.0 million (Q2 2025).